NCT05509933View on ClinicalTrials.gov

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

PHASE3RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

Engraftment Syndrome

Interventions

DRUG

Budesonide

budesonide starting day 5 after transplant

Trial Locations (1)

48202

RECRUITING

Henry Ford Health System, Detroit

All Listed Sponsors

lead

Henry Ford Health System

OTHER